Susan Pandya: The beginning of a new era for patients living with grade 2 IDH-mutant glioma

Susan Pandya, Vice President of Clinical Development and Global Head of Cancer Metabolism at Servier, shared a post by Servier Pharmaceuticals on LinkedIn, adding:

“Today’s FDA approval marks the beginning of a new era for patients living with grade 2 IDH-mutant glioma – a community that has been waiting more than 20 years for a therapeutic breakthrough.

From the beginning, our journey to develop this novel therapy was ambitious, but rooted in innovative science and dedicated collaborations across the neuro-oncology community. Our mission was to strive to meet the needs of patients and fundamentally change the way the disease is treated.

I am humbled and immensely grateful to have reached this milestone alongside such esteemed colleagues, and most importantly the patients, caregivers, and clinical investigators who made this breakthrough possible.”

Quoting Servier Pharmaceuticals’ post

“Breaking News

We are thrilled to announce that today, the U.S. FDA has approved the first targeted therapy for Grade 2 IDH-mutant glioma. This is the first significant treatment breakthrough for this relentless condition in nearly 25 years.

Thank you to the dedicated study participants, researchers, and clinical investigators who made this achievement possible.

Learn more about this approval and Servier’s mission to bring transformative new therapies to patients.”

Proceed to the video attached to the post.
Source: Susan Pandya/LinkedIn and Servier Pharmaceuticals/LinkedIn